Re­call re­port: More Chan­tix lots pulled from shelves as ni­trosamine woes con­tin­ue

An­oth­er four lots of Pfiz­er’s pop­u­lar an­ti-smok­ing drug have been re­called due to high lev­els of ni­trosamine, the FDA an­nounced.

Pifz­er halt­ed dis­tri­b­u­tion of Chan­tix and re­called four lots of the drug in June, af­ter find­ing el­e­vat­ed lev­els of can­cer-caus­ing ni­trosamines. De­spite the re­call, an of­fi­cial at Pfiz­er Ko­rea said the com­pa­ny be­lieves the ben­e­fits of the non-smok­ing drug out­weigh any po­ten­tial risk of ex­po­sure to ni­trosamines, and that those who have been tak­ing it should con­tin­ue to do so.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER